CClinicalTrials.gg
CompletedNCT02441855Updated Jun 4, 2015

Potential Role for Echocardiography in Adult Patients With Community-Acquired Pneumonia

An observational study in Community-acquired Pneumonia, sponsored by Muğla Sıtkı Koçman University. Completed at 1 site in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-04.

Sponsored by Muğla Sıtkı Koçman University · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
210
Ages
18 Years and older
Sex
All
01

Study summary

Despite the efficacy of modern treatment, community-acquired pneumonia (CAP) is the the leading cause of death. Prognostic scores have been developed to estimate the risk of adverse outcome. Several serum biomarkers have been also investigated in patients with CAP. A growing number of echocardiographic markers have been evaluated as possible predictors of prognosis in patients with pulmonary and infectious diseases such as sepsis, septic shock, human immunodeficiency virus infection, pulmonary tuberculosis, and chronic obstructive pulmonary disease. As echocardiography is a non-invasive, reliable, cost-effective, and reproducible diagnostic tool to evaluate cardiac function and structures, the investigators aimed to investigate left and right ventricular functions and aortic elastic properties in CAP patients. Furthermore, the investigators also aimed to observe relationships between echocardiographic findings and inflammatory and cardiac serum biomarkers in patients with CAP.

Read the detailed description

Despite the efficacy of modern treatment, community-acquired pneumonia (CAP) is the the leading cause of death. Prognostic scores, like the CURB-65 (confusion, urea, respiratory rate, arterial blood pressure and age) score and the pneumonia severity index (PSI) have been developed and validated to estimate the risk of adverse outcome and to register a patient with CAP for hospital admission. Serum biomarkers have been also investigated in patients with CAP like Procalcitonin and C-reactive protein. Elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) has been shown to be associated with adverse prognosis in several cardiac conditions and critically ill patients. NT-proBNP is also shown to be important predictor in the emergency department and in hospitalized patients with CAP. A growing number of echocardiographic markers have been evaluated as possible predictors of prognosis in patients with pulmonary and infectious diseases such as sepsis, pulmonary tuberculosis, and chronic obstructive pulmonary disease. Although effects of pneumonia on cardiac structures is theoretically possible due to increased systemic inflammatory activity, prothrombotic conditions, biomechanical stress on coronary arteries, variations in coronary arterial tone, and altered myocardial metabolic balance during infections, the role of transthoracic echocardiography has never been evaluated in patients with CAP. As echocardiography is a non-invasive, reliable, cost-effective, and reproducible diagnostic tool to evaluate cardiac function and structures, the investigators aimed to investigate left and right ventricular functions and aortic elastic properties in CAP patients. Furthermore, the investigators also aimed to observe relationships between echocardiographic findings and inflammatory and cardiac serum biomarkers in patients with CAP.

02

Conditions studied

  • Community-acquired Pneumonia

Browse trials for

03

In context

Pneumonia

2,044 studies on the registry are indexed under Pneumonia; 283 are open to participants now.

This study's enrollment of 210 is close to the median of 203 across 688 observational studies indexed under Pneumonia.

Browse Pneumonia studies →

Lead sponsor

Muğla Sıtkı Koçman University is the lead sponsor of 112 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pneumonia group is defined as patients with community acquired pneumonia diagnosis hospitalised through emergency department. The control group will be consisted of consecutive sex- and age-matched patients admitted to the emergency department.

Inclusion criteria

  • ≥ 18 years of age

Exclusion criteria

Exclusion Criteria:

  • Patients with active pulmonary tuberculosis
  • Hospital-acquired pneumonia
  • Severely immunocompromised patients
  • Patients undergoing chronic dialysis
  • Patients sent for ambulatory treatment
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
210 participants (actual)
Patient registry
No

Groups and cohorts

  • pneumonia

    patients with community-acquired pneumonia

    Device: echocardiography

  • control

    patients admitted to emergency department with shortness of breath

    Device: echocardiography

Interventions

  • Deviceechocardiography

    echocardiography: Left and right ventricular functions and aortic elastic properties.

06

What researchers measure

Primary outcomes

  1. the TAPSE value to discriminate patients with pneumonia

    the TAPSE (Tricuspid annular plane systolic excursion ) value to discriminate patients with pneumonia

    Time frame: 1 month

Secondary outcomes

  1. the BNP value to discriminate patients with pneumonia

    the BNP (B-type natriuretic peptide) value to discriminate patients with pneumonia

    Time frame: 1 month

07

Study locations

1 site
  • Mugla Sitki Kocman University Education and Research Hospital
    Mugla, Turkey
08

References and documents

Publications

  • Biteker FS, Biteker M, Basaran O, Dogan V, Ozlek B, Yildirim B, Ozlek E, Celik O. A small pericardial effusion is a marker of complicated hospitalization in patients with community-acquired pneumonia. J Crit Care. 2018 Apr;44:294-299. doi: 10.1016/j.jcrc.2017.11.030. Epub 2017 Nov 23. PubMed 29247912 ↗
  • Biteker FS, Basaran O, Dogan V, Caylak SD, Yildirim B, Sozen H. Prognostic value of transthoracic echocardiography and biomarkers of cardiac dysfunction in community-acquired pneumonia. Clin Microbiol Infect. 2016 Dec;22(12):1006.e1-1006.e6. doi: 10.1016/j.cmi.2016.08.016. Epub 2016 Sep 3. PubMed 27596535 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 4, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02441855
Lead sponsor
Muğla Sıtkı Koçman University
Responsible party
Ozcan Basaran (M.D, Muğla Sıtkı Koçman University) — Principal investigator
First posted
May 12, 2015
Start date
Mar 2015
Primary completion
May 2015
Completion
May 2015
Last update
Jun 4, 2015

Study contacts

Murat Biteker, Assoc. Prof.
study director · Muğla Sıtkı Koçman University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion